Lung basaloid SCC has better outcomes than other SCCs

  • Lung Cancer

  • Par Kelli Whitlock Burton
  • Résumés d'articles
L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte. L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte.

Takeaway

  • Among patients with squamous cell carcinoma (SCC) lung cancer, those with basaloid SCC (BSCC) have significantly better outcomes than those with keratinizing SCC (KSCC) or non-KSCC.

Why this matters

  • Prior studies comparing outcomes among the 3 subtypes offered conflicting results.

Study design

  • 4743 patients with lung SCC from the Surveillance, Epidemiology, and End Results database.
  • Funding: National Natural Science Foundation of China.

Key results

  • 64.5% had KSCC, 29.1% NKSCC, and 6.4% BSCC.
  • 5-year OS:
    • 37.2% with BSCC.
    • 20.4% with KSCC.
    • 23.9% with NKSCC.
  • Better OS with BSCC than with KSCC or NKSCC (P<.001 for both>
  • Better OS with NKSCC than KSCC (P=.001).
  • 5-year cancer-specific survival (CSS):
    • 48.1% for BSCC.
    • 66.6% for KSCC.
    • 61.8% for NKSCC.
  • Better CSS with BSCC than with KSCC or NKSCC (P<.001 for both>
  • Better CSS with NKSCC than KSCC (P<.001>
  • All-cause mortality was similar among groups.
  • After propensity score matching:
    • Better 5-year OS with BSCC than with KSCC (P=.036) or NKSCC (P=.016).
    • No significant difference between KSCC and NKSCC.
  • After propensity score matching: 
    • Better 5-year CSS with BSCC than with KSCC or NKSCC (P=.033 for both).
    • No significant difference between KSCC and NKSCC.

Limitations

  • Retrospective study.